Data / Federal rules / 2026-17536

Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV

The Drug Enforcement Administration published this final rule in the Federal Register on August 27, 2026. It took effect on August 27, 2026. Comments closed on September 28, 2026.

SpecStream is the live web data engine for teams and agents. It reads every rule and proposed rule in the Federal Register each morning, and this page is that reading. Name your industry once and new rules, comment deadlines and effective dates arrive in your sheet, CRM, Slack or agent as they are published.

Get new rules for your industry

What the agency says

On May 29, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Cypsedo (cipepofol) for induction of general anesthesia in adults undergoing surgery. The Department of Health and Human Services provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place cipepofol, chemically known as 2-[(1R)-1-cyclopropylethyl]-6- isopropylphenol, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing cipepofol in schedule IV of the CSA.

Key facts

Document number: 2026-17536
Type: Final rule
Action: Interim final rule; request for comments
Agency: Justice Department; Drug Enforcement Administration
Published: August 27, 2026
Takes effect: August 27, 2026
Comments due: September 28, 2026
Dates: This rule is effective August 27, 2026. Comments must be submitted electronically or postmarked on or before September 28, 2026. The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.
Docket: Docket No. DEA 1713
Code of Federal Regulations: 21 CFR 1308
Topics: Administrative practice and procedure; Drug traffic control; Reporting and recordkeeping requirements
Pages: 7

The document on federalregister.gov PDF

Other documents from the Drug Enforcement Administration

Document	Type	Published
Schedules of Controlled Substances: Temporary Placement of 7- Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I 2026-20943	Proposed rule	Oct 14
Schedules of Controlled Substances: Temporary Placement of MGM-15 and MGM-16 in Schedule I 2026-20942	Proposed rule	Oct 14
Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products 2026-20757	Final rule	Oct 9
Schedules of Controlled Substances: Placement of O-Desmethyltramadol in Schedule I; Correction 2026-20748	Final rule	Oct 9
Extension of Reexportation Period. 2026-20084	Proposed rule	Oct 1
Schedules of Controlled Substances: Placement of 4-Hydroxy-N,N-Diisopropyltryptamine (4-OH-DiPT), 5-Methoxy-alpha-Methyltryptamine (5-MeO-AMT), 5-Methoxy-N-Methyl-N-Isopropyltryptamine (5-MeO-MiPT), 5-Methoxy-N,N-Diethyltryptamine (5-MeO-DET), and N,N-Diisopropyltryptamine (DiPT) Into Schedule I 2026-19400	Proposed rule	Sep 23
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I 2026-19231	Final rule	Sep 21
Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act 2026-17531	Final rule	Aug 27

Everything from the Drug Enforcement Administration · Rules on administrative practice and procedure · Rules on drug traffic control · Rules on reporting and recordkeeping requirements · Published in August 2026

Read from the Federal Register API, last updated 2026-10-23. The document on federalregister.gov is the official record; dates and dockets can change through later corrections. Free to reuse with credit to SpecStream under CC BY 4.0.